Petr Bely outlined five areas for the development of innovative drug therapy in Russia at the consilium «Healthcare. Looking into the future»
Petr Bely, the Chairman of the Board of Directors of Promomed Group made a report titled «The future of Russian pharmaceutical science and industry. Import Substitution» at the consilium «Healthcare. Looking into the future».
He pointed out five main directions for the development of innovative drug therapy in the country and outlined concrete steps to implement this concept.
«First. We have an excellent experience in the rapid launch of innovative drugs that we gained during the pandemic. If we manage to extend and expand the scope of the government Decree No. 441, which creates conditions for the rapid launch of domestic innovative drugs, then we will be able to achieve the same tangible results in other therapeutic areas.
Prices are the second issue. Only domestic innovative drugs, which are made without additional costs, can solve ensure the effective and affordable drug supply. It is necessary to make sure at the political level, at the level of the state vision, that innovative domestic medicines are given the way.
Third, domestic active pharmaceutical ingredients. It is very important to foster all efforts to ensure that each domestic manufacturer of medicines has its own production of the substance.
The fourth aspect that is very important to us. Interaction between industry and education. Continuing education of doctors is needed. Suppose that an innovative drug appears. We need to make sure that information about innovative domestic drugs becomes known to the professional community very quickly. We, as a pharmaceutical industry, are ready to do a lot for this. We are ready to create programs.
Fifth but not least, helping children. We need to consolidate the priority of innovative drugs for children at the level of state policy and motivate Russian companies to launch pediatric drugs along with the most advanced drugs for adults. Our company conducts a lot of clinical trials.»
Source:
